Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 INCMGA00012 in previously platinum-treated advanced anal squamous cell carcinoma
NL-OMON48162Phase 2Withdrawn
- Sponsor
- Incyte
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab in anal squamous cell carcinoma (SCCA), sponsored by Incyte. Primary endpoint: Overall response rate. Planned start Oct 2018; status: withdrawn.
02
Drugs
retifanlimab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NL-OMON48162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48162.